In the streptozotocin-induced diabetic mice model, scopoletin (compound 15, 0.01 g/100 g diet) reduced blood glucose and glycated hemoglobin, glucose intolerance, hepatic lipid accumulation and downregulated hepatic gene expression of triglyceride and cholesterol synthesis and inflammation (TLR4, MyD88, NF-κb1, TNF-α, and IL-6). The gene discussed is MYD88; the disease is Glucose intolerance.